Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-operable or metastatic non-functioning, well differentiated advanced GI NET, confirmed by cytology or histology. In case of liver metastasis, neuroendocrine tumours of unknown origin are accepted.~* Confirmation of diagnosis of neuroendocrine carcinoma of low to intermediate histology grade~* Radiologically documented disease progression within 12 months prior to inclusion in the study. If the patient received anticancer treatment within the past 12 months, disease progression must be documented by radiology during or after taking this medication~* Adequate bone marrow. liver and renal function~Exclusion Criteria:~* Previous treatment with mTOR inhibitors (sirolimus, temsirolimus, everolimus, deforolimus).~* Patients with any serious disease and/or an uncontrolled clinical condition~* Patients on chronic treatment with corticosteroids or any other immunosuppressive agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus + Octreotide LAR treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).